NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

4.4872 -0.3728 (-7.67%)
At close: May 17 at 4:00 PM EDT
4.5500 +0.06 (+1.40%)
After hours: May 17 at 7:10 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Stephen C. Glover Co-Founder, Chairman, CEO & President 775k -- 1960
Mr. Peter Wolfe CFO & Secretary 477.5k -- 1968
Ms. Karen A. Cashmere Chief Commercial Officer 410k -- 1952
Ms. Melda Uzbil O'connell Senior Vice President of Corporate Development -- -- --
Dr. Pablo A. Guzman FACC, M.D. Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board -- -- 1950

ZyVersa Therapeutics, Inc.

2200 N. Commerce Parkway
Suite 208
Weston, FL 33326
United States
754 231 1688 https://www.zyversa.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
7

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.

Corporate Governance

ZyVersa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

May 15, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 27, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 25, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 19, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 8, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

March 1, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2024 at 12:00 AM UTC

S-8: Offering Registrations

December 22, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers